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Introduction. Primary signet ring cell carcinoma (SRCC) of the lung is a very rare disease. We describe a new case of
primary SRCC of the lung with cerebellar metastasis, which responded well to the therapeutic approach with cisplatin and
docetaxel. Case Report. A 41-year-old female patient (nonsmoker) was consulted to our oncology outpatient clinic after cerebellar
metastasectomy. The histopathological diagnosis was SRCC metastasis. The primary tumor was unknown. The PET-CT imaging
showed a hypermetabolic mass in the right middle lobe of the lung and hypermetabolic mediastinal lymph node stations.
Oesophagogastroduodenoscopy and colonoscopy showed no evidence of gastrointestinal system tumor. The clinical diagnosis of
primary SRCC of the lung was made and the administration of six rounds of cisplatin and docetaxel treatment was planned. After
the chemotherapy the PET-CT scan to evaluate the therapy response showed full metabolic regression of the primary tumor and
themediastinallymphnodes.Therewasnoevidenceofnewmetastasis.Conclusion.PrimarySRCCofthelungisaveryraredisease
with poor prognosis. There are not many cases in literature and no standardized chemotherapy protocols. Cisplatin and docetaxel
may be a good treatment option.
1. Introduction
P r i m a r yS R C Co ft h el u n gi sav e r yr a r ed i s e a s e .F i r s t
described by Kish et al. in 1989, it is reported that incidence
of primary SRCC of the lung varies from 0.14% to 1.9% of all
lung cancers [1]. The largest series was taken by Tsuta et al. in
which39of2640surgicallyresectedprimarylungcarcinomas
showed SRCC components. Mean age of the patients was
54.6 years, male to female ratio was 1.16:1.00, and 26 patients
(66.7%) were smokers. The size of the SRCC component of
the tumor positively correlated with the aggressiveness of
t h et u m o ra n dp o o ro u t c o m e .Th e5 - y e a rs u r v i v a lw a s2 8 %
[2].
2. Case
A 41-years-old female patient (nonsmoker) was consulted to
our oncology outpatient clinic by the neurosurgery clinic
afteracerebellarmetastasectomy.ThepreopCTscanshowed
a right cerebellar hypodense lesion with the dimension of 5×
5cm(Figure 1).
Thehistopathologicalexaminationofthemetastasectomy
material showed SRCC metastasis with positive immunos-
taining for CEA, CK 7, and TTF-1. The immunostaining with
CK 20, ER, COX2, CK 14, CDX2, and MUC2 was negative.
The histopathological morphology was shown Figures 2(a),
2(b),a n d2(c).
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Figure 1: The preop CT scan showed a right cerebellar hypodens
lesion.
In order to find the primary tumor a PET-CT scan, oeso-
phagogastroduodenoscopy and colonoscopy was planned.
The endoscopic evaluation of the gastrointestinal system
showed no evidence of tumor. The PET-CT scan showed
a2 6× 23mm sized hypermetabolic lesion (SUVmax: 12.1)
in the right middle lobe of the lung, multiple 10mm sized
hypermetabolic lymph nodes (SUVmax: 5.7) at station 10R,
and a 21 × 19mm sized hypermetabolic (SUVmax: 12.4)
l y m p hn o d ea ts t a t i o n1 1 Ri nt h em e d i a s t i n u m .Th ec l i n i c a l
diagnosiswasprimarySRCCofthelung.Thepatientreceived
cranial radiotherapy. After the radiotherapy we decided to
administrate the patient six rounds of cisplatin and docetaxel
regimen. The PET-CT scan to reevaluate the therapy after
the 3 rounds of the chemotherapy showed decreased FDG
uptake(SUVmax:5.1)andadecreaseinthesizeoftheprimary
lesion, which we interpreted as partial regression. The hilar
metastatic lymph nodes showed nearly full regression and
couldbarelybevisualizedinthePET -CTimages.W edecided
to complete the cisplatin and docetaxel protocol. The PET-
CT scan after the completion of the chemotherapy showed
ad e c r e a s ei ns i z e( 1 9× 25mm) and metabolic regression
(SUVmax: 2.6) of the primary tumor in the right middle
lobe of the lung, there was no hypermetabolic pathological
lymphadenopathies in the mediastinum. In the left axilla,
a7× 14mm sized nodular lesion with slightly increased
F D Gu p t a k e( S U V m a x :1 . 3 )w a sd e t e c t e d .Th e r ew a sn o
pathological FDG uptake in the rest of the body.
3. Discussion
Primary SRCC of the lung is a very rare disease. The largest
series was taken by Tsuta et al. in which 39 of 2640 cases
surgically resected primary lung carcinomas showed SRCC
components. Mean age of the patients was 54.6 years, male-
to-femaleratiowas1.16:1.00,andtwentysixpatients(66.7%)
were smokers. The size of the SRCC component positively
correlated with the aggressivenes of the tumor and poor
outcome. The 5-year survival was 28% [2].
B e c a u s eo ft h er a r e n e s so ft h ed i s e a s e ,i ti si m p o r t a n tt o
distinguish the primary SRCC of the lung from metastatic
(a)
(b)
(c)
Figure 2: (a) Malign epithelial infiltration in the cerebellum with
signet-ring cell morphology. HE x100. (b): Cell groups in the tumor
showpositivestainingwithcytoplasmicCK7.CK7x200.(c)Positive
nuclear staining with TTF-1 in the signet-ring tumor cells. TTF-1
x200.
SRCC’s from other sites of the body like stomach, colon,
breast, urinary tract which are more common.
Immunohistochemicalstudiesandmoleculardiagnostics
should help in making the differential diagnosis. The studies
of Merchant et al. with 32 SRCC’s from various organs (17
lung, 5 breast, and 5 stomach and 5 colon) showed that
82.4% of pulmonary SRCC’s were TTF-1 positive and the
cytokeratine profile CK 7 +/CK20 - was identified in 94.1%
of the pulmonary SRCC cases. Villin was in 29.4% of the
cases positive [3]. Positivity for both TTF-1 and Napsin-A is
a strong indicator for pulmonary origin [4, 5].
Hayashi et al. reported 5 cases of primary lung SRCC.
80% of the cases were immunoreactive for lactoferrin, 100%Case Reports in Oncological Medicine 3
s h o w e dK - R a sm u t a t i o n s ,1 0 0 %w e r ep o s i t i v ef o rM U C1a n d
100% were negative for MUC 2. MUC 1, is most commonly
seen in SRCC and the solid adenocarcinoma of the lung than
in SRCC of other organ sites [6].
A l t h o u g hu n c o m m o n l y ,T T F - 1c a na l s ob ee x p r e s s e di n
carcinomas originating from other primary sites (e.g., colon)
[7]. On the other side negativity for TTF-1 does not exclude
pulmonary SRCC if the tumor is CK 7, positive. In this case
metastatic tumor from other body sites need to be excluded
clinically [8]. In our case the tumor was positive for CEA,
CK 7 and TTF-1 and negative for CK 20, ER, COX2, CK
14, CDX2, and MUC2. It should also be noted that in 70%
of pulmonary adenocarcinomas ALK gene rearrangement
can be identified, when the SRCC component is >10% [9].
Shawetal.demonstratedthatALKthyroxinekinaseinhibitor
(crizotinib)therapyhaspositiveimpactonimprovedsurvival
[10].
A comprehensive, retrospective population-based analy-
sisoftheprimarySRCCofthelungwiththeadenocarcinoma
of the lung by Ou et al. showed that the patients with
primary SRCC are significantly younger than patients with
adenocarcinoma, with a significantly higher proportion of
poorly differentiated tumor and stage IV disease and no
difference in the distribution of gender and ethnicity. Never
smokers comprised a higher proportion of patients with
SRCC (30.8%) compared to patients with adenocarcinoma
(11.0%). Never smokers with SRCC were younger and had
an improved overall survival (median age: 55 years, median
overallsurvival:8months)thansmokerswithSRCC(median
age: 59 years, median overall survival: 4.5 months). Patients
with SRCC had decreased overall survival compared to
adenocarcinoma patients [11]. Our patient is a 41-year-old,
female, never smoker. Seven months after diagnosis and six
roundsofcisplatinanddocetaxeltherapy,sheiswellandalive
w i t has a t i s f a c t o ryr e s p o n s et oc h e m o t h e r a p y .
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